MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., ...
ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc (MXCT)., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback